This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sun, Q. N.
Right arrow Articles by Graybill, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sun, Q. N.
Right arrow Articles by Graybill, J. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2002, p. 2310-2312, Vol. 46, No. 7
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.7.2310-2312.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

In Vivo Activity of Posaconazole against Mucor spp. in an Immunosuppressed-Mouse Model

Qiu N. Sun,1,2 Laura K. Najvar,1 Rosie Bocanegra,1 David Loebenberg,3 and John R. Graybill1*

Division of Infectious Disease, Department of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229-3900,1 Department of Dermatology, Beijing Union Medical University Hospital, Beijing, 100730 People's Republic of China,2 Schering-Plough Research Institute, Kenilworth, New Jersey 07033-13003

Received 31 October 2001/ Returned for modification 1 December 2001/ Accepted 31 March 2002

The in vivo activities of posaconazole, itraconazole, and amphotericin B in neutropenic mice with zygomycosis were compared. The in vitro MICs of posaconazole and itraconazole for the strains of Mucor spp. used in this study ranged from 0.125 to 8 µg/ml and 0.25 to 8 µg/ml, respectively. The in vitro MIC range for amphotericin B is 0.125 to 0.25 µg/ml. At twice-daily doses of >=15 mg/kg of body weight, posaconazole prolonged the survival of the mice and reduced tissue burden.

* Corresponding author. Mailing address: Division of Infectious Disease (7881), Department of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900. Phone: (210) 617-5300, ext. 4793. Fax: (210) 949-3456. E-mail: graybill{at}uthscsa.edu.

Antimicrobial Agents and Chemotherapy, July 2002, p. 2310-2312, Vol. 46, No. 7
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.7.2310-2312.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Ruiz-Cendoya, M., Marine, M., Rodriguez, M. M., Guarro, J. (2009). Interactions between Triazoles and Amphotericin B in Treatment of Disseminated Murine Infection by Fusarium oxysporum. Antimicrob. Agents Chemother. 53: 1705-1708 [Abstract] [Full Text]  
  • Koonce, R. C., Price, C. S., Sutton, D. A., Wickes, B. L., Montero, P. N., Morgan, S. J. (2009). Lower-Extremity Zygomycosis in a Patient with Traumatic Injuries. A Case Report. JBJS 91: 686-692 [Full Text]  
  • Ibrahim, A. S., Gebremariam, T., Schwartz, J. A., Edwards, J. E. Jr., Spellberg, B. (2009). Posaconazole Mono- or Combination Therapy for Treatment of Murine Zygomycosis. Antimicrob. Agents Chemother. 53: 772-775 [Abstract] [Full Text]  
  • Ruiz-Cendoya, M., Marine, M., Guarro, J. (2008). Combined therapy in treatment of murine infection by Fusarium solani. J Antimicrob Chemother 62: 543-546 [Abstract] [Full Text]  
  • Almyroudis, N. G., Sutton, D. A., Fothergill, A. W., Rinaldi, M. G., Kusne, S. (2007). In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal Agents. Antimicrob. Agents Chemother. 51: 2587-2590 [Abstract] [Full Text]  
  • Gelston, C. D., Durairaj, V. D., Simoes, E. A. F. (2007). Rhino-orbital Mucormycosis Causing Cavernous Sinus and Internal Carotid Thrombosis Treated With Posaconazole. Arch Ophthalmol 125: 848-849 [Full Text]  
  • Sansone-Parsons, A., Krishna, G., Simon, J., Soni, P., Kantesaria, B., Herron, J., Stoltz, R. (2007). Effects of Age, Gender, and Race/Ethnicity on the Pharmacokinetics of Posaconazole in Healthy Volunteers. Antimicrob. Agents Chemother. 51: 495-502 [Abstract] [Full Text]  
  • Chiang, L. Y., Ejzykowicz, D. E., Tian, Z.-Q., Katz, L., Filler, S. G. (2006). Efficacy of ambruticin analogs in a murine model of invasive pulmonary aspergillosis.. Antimicrob. Agents Chemother. 50: 3464-3466 [Abstract] [Full Text]  
  • Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Buitrago, M. J., Monzon, A., Rodriguez-Tudela, J. L. (2006). Head-to-Head Comparison of the Activities of Currently Available Antifungal Agents against 3,378 Spanish Clinical Isolates of Yeasts and Filamentous Fungi. Antimicrob. Agents Chemother. 50: 917-921 [Abstract] [Full Text]  
  • Liang, K. P., Tleyjeh, I. M., Wilson, W. R., Roberts, G. D., Temesgen, Z. (2006). Rhino-Orbitocerebral Mucormycosis Caused by Apophysomyces elegans.. J. Clin. Microbiol. 44: 892-898 [Abstract] [Full Text]  
  • Lopez-Oviedo, E., Aller, A. I., Martin, C., Castro, C., Ramirez, M., Peman, J. M., Canton, E., Almeida, C., Martin-Mazuelos, E. (2006). Evaluation of Disk Diffusion Method for Determining Posaconazole Susceptibility of Filamentous Fungi: Comparison with CLSI Broth Microdilution Method. Antimicrob. Agents Chemother. 50: 1108-1111 [Abstract] [Full Text]  
  • Schwarz, P., Bretagne, S., Gantier, J.-C., Garcia-Hermoso, D., Lortholary, O., Dromer, F., Dannaoui, E. (2006). Molecular Identification of Zygomycetes from Culture and Experimentally Infected Tissues. J. Clin. Microbiol. 44: 340-349 [Abstract] [Full Text]  
  • Antachopoulos, C., Meletiadis, J., Roilides, E., Sein, T., Walsh, T. J. (2006). Rapid Susceptibility Testing of Medically Important Zygomycetes by XTT Assay. J. Clin. Microbiol. 44: 553-560 [Abstract] [Full Text]  
  • Greenberg, R. N., Mullane, K., van Burik, J.-A. H., Raad, I., Abzug, M. J., Anstead, G., Herbrecht, R., Langston, A., Marr, K. A., Schiller, G., Schuster, M., Wingard, J. R., Gonzalez, C. E., Revankar, S. G., Corcoran, G., Kryscio, R. J., Hare, R. (2006). Posaconazole as Salvage Therapy for Zygomycosis. Antimicrob. Agents Chemother. 50: 126-133 [Abstract] [Full Text]  
  • Karanth, M, Taniere, P, Barraclough, J, Murray, J A (2005). A rare presentation of zygomycosis (mucormycosis) and review of the literature. J. Clin. Pathol. 58: 879-881 [Abstract] [Full Text]  
  • Spellberg, B., Edwards, J. Jr., Ibrahim, A. (2005). Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management. Clin. Microbiol. Rev. 18: 556-569 [Abstract] [Full Text]  
  • Gil-Lamaignere, C., Hess, R., Salvenmoser, S., Heyn, K., Kappe, R., Muller, F.-M. C. (2005). Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes. J Antimicrob Chemother 55: 1016-1019 [Abstract] [Full Text]  
  • Ibrahim, A. S., Bowman, J. C., Avanessian, V., Brown, K., Spellberg, B., Edwards, J. E. Jr., Douglas, C. M. (2005). Caspofungin Inhibits Rhizopus oryzae 1,3-{beta}-D-Glucan Synthase, Lowers Burden in Brain Measured by Quantitative PCR, and Improves Survival at a Low but Not a High Dose during Murine Disseminated Zygomycosis. Antimicrob. Agents Chemother. 49: 721-727 [Abstract] [Full Text]  
  • Graybill, J. R., Hernandez, S., Bocanegra, R., Najvar, L. K. (2004). Antifungal Therapy of Murine Aspergillus terreus Infection. Antimicrob. Agents Chemother. 48: 3715-3719 [Abstract] [Full Text]  
  • Graybill, J. R., Najvar, L. K., Johnson, E., Bocanegra, R., Loebenberg, D. (2004). Posaconazole Therapy of Disseminated Phaeohyphomycosis in a Murine Model. Antimicrob. Agents Chemother. 48: 2288-2291 [Abstract] [Full Text]  
  • Dannaoui, E., Meis, J. F. G. M., Loebenberg, D., Verweij, P. E. (2003). Activity of Posaconazole in Treatment of Experimental Disseminated Zygomycosis. Antimicrob. Agents Chemother. 47: 3647-3650 [Abstract] [Full Text]  
  • Courtney, R., Pai, S., Laughlin, M., Lim, J., Batra, V. (2003). Pharmacokinetics, Safety, and Tolerability of Oral Posaconazole Administered in Single and Multiple Doses in Healthy Adults. Antimicrob. Agents Chemother. 47: 2788-2795 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»